NYMALIZE (Nimodipine) Patent Expiration, LOE Window & CMS Spending

NYMALIZE (Nimodipine) by Azurity: FDA Orange Book core substance LOE 2038-04-16, 1 AB generics, $0 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN203340 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-04-16
Last Listed Patent or Exclusivity Date2038-04-16
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)9 WAC filings (max 26.4% 2-yr change)